Pfizer’s Earnings from Chantix/Champix Drop By 1%
Date: 30th January 2013
According to a latest disclosure by Pfizer Inc., the earnings from its quit smoking medicine Chantix/Champix (varenicline) decreased by 1% to $174 million. Pfizer also reveals that its income from Lyrica, the medicine used for treating neuropathic pain, fibromyalgia and epilepsy, was enhanced by 2% to $323 million.
The sales of all these medicines were related to Pfizer’s fourth quarter net income, which was increased to $6.32 billion. News sources reveal that Pfizer’s net income increased significantly in comparison to $1.44 billion in the year-earlier period.
However, Pfizer may consider about dividing its drug business and analysts are getting more excited about this new prospect.